Mirati Therapeutics to Present Late-Breaking Data That Advance the Understanding of Synthetic Lethal PRMT5 Inhibitors in MTAP-Deleted Cancers at AACR 2021
Share this article Share this article SAN DIEGO, March 10, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, today announced it will present initial preclinical data on the Company's synthetic lethal PRMT5 inhibitor during a late-breaking minisymposium at the American Association for Cancer Research (AACR) Virtual Annual Meeting taking place April 10-15, 2021. "At Mirati, we are applying leading-edge drug discovery strategies, such as synthetic lethality, to translate this exciting research approach into meaningful, targeted therapeutic ...
Source: prnewswire.com